AMSTERDAM and WASHINGTON, March 17,
2017 /PRNewswire/ -- At the 2017 American College of
Cardiology's Annual Scientific Session & Expo (ACC.17), Royal
Philips (NYSE: PHG, AEX: PHIA) will showcase a broad range of
integrated, patient-centric solutions designed to address the
prevention, diagnosis, minimally invasive treatment and chronic
care at home of cardiac conditions. As a global leader in health
technology, Philips will demonstrate how its suite of cardiology
solutions comprising imaging systems, smart devices, clinical
informatics and services, help transform care pathways and provide
clinical insights that contribute to life-changing
opportunities.
With a continued shift away from fee-for-service payment models
and transition from volume to value-based care, healthcare
organizations are challenged to help prevent and reduce costs while
improving the quality of care. At ACC.17, Philips will demonstrate
how its comprehensive suite of cardiology solutions enable
hospitals to reduce system response and streamline processes to
improve the management of cardiac patients in emergency situations.
By enabling seamless communication across the health continuum,
from home to hospital and back, Philips is bridging the gap in
patient flow before entrance to the hospital and after discharge,
which is critical to reducing costs and achieving optimal outcomes
for patients.
"As a focused leader in health technology, Philips aims to
provide integrated solutions across the health continuum from
healthy living and prevention, to diagnosis, treatment and after
care at home, in order to combat the rising incidence of chronic
diseases such as those caused by cardiovascular conditions," said
Bert van Meurs, Business Leader,
Image Guided Therapy. "We offer a broad portfolio of innovative
solutions to optimize the image-guided minimally invasive treatment
of cardiovascular conditions, while managing costs."
Philips will exhibit the company's advanced, connected health
offerings in the cardiology space at ACC.17, including:
- Azurion – Philips' recently launched, next generation
image-guided therapy platform allows clinicians to easily and
confidently perform a wide range of routine and complex procedures,
helping them to optimize interventional lab performance and provide
superior care. Azurion is powered by ConnectOS, a new operating
system that provides a seamless integration of real-time
information from all relevant technologies in the interventional
lab. ACC.17 attendees will have one of the first opportunities to
interact with Azurion firsthand.
- Evolution 3.0 – Philips introduces the X8-2t Live 3D
TEE transducer, which allows for new levels of Live 3D imaging
bringing the next generation of 3D TEE features, including a new
acoustic design with higher frequencies and bandwidth to provide
increased resolution and tissue filling. Fast, easy and confident
transthoracic and transesophageal echo allows clinicians to
diagnose surgical pathology in real time.
- HeartModelAI – Philips' premier Anatomical
Intelligence Ultrasound (AIUS) application brings advanced
automated quantification, 3D views, robust reproducibility and
significant time-savings to echocardiography quantification.
Results of a multi-center study validating the robustness of
Philips HeartModelAI were recently published in the
European Heart Journal.
- IntelliSpace Cardiovascular – Provides access to
advanced cardiovascular informatics applications, brings
multi-modality images and clinical tools together in a single
workspace for integrated clinical decision support. It seamlessly
integrates with IntelliSpace Portal advanced visualization
solution, IntelliSpace ECG data management solution, and the
Philips Xper Information Management cath lab workflow
solution.
- DreamStation BiPAP autoSV Advanced – Designed to deliver
optimal ventilation with minimal intervention for patients with
central sleep apnea, complex sleep apnea and periodic breathing.
Philips' clinically proven algorithm provides support when needed
to help reduce events and normalize ventilation and works with the
patient's breathing pattern to minimize applied pressure, pressure
support and machine breaths which can help patients experience
comfortable, restful sleep.
Also at this year's conference, new groundbreaking iFR (instant
wave-Free Ratio) outcome results from over 4,500 patients will be
announced on Saturday, March 18 at
10:45 a.m. The data, which represent
the largest randomized coronary physiology outcome studies to date,
has the potential to help shape revascularization guidelines. The
announcement and presentation of the outcome data follows Philips'
announcement last year of three clinical studies designed to assess
the safety of deferring cardiovascular interventions using the
company's proprietary iFR pressure measurement technology.
In addition to presenting data around the benefits of iFR
technology, Philips will host "Cardiology Talks," a program of
short talks and conversation on key findings, trends and ideas
impacting the cardiology specialty today. During the 20-minute
sessions held in the Forum area of the Philips booth, clinicians,
scientists and thought leaders will share their experiences and
perspectives, discuss innovations, and invite attendees to join in
the conversation. To view the full schedule of sessions, visit the
Philips Cardiology Talks page.
For more information on Philips' integrated cardiology
solutions, visit Philip's booth (#1024) at ACC.17 or visit the
Philips event page. Follow the #ACC17 conversation via
@PhilipsLiveFrom and @PhilipsHealth.
For further information, please contact:
Alicia
Cafardi
Philips Group Press Office
Tel: +1 412-523-9616
Email: Alicia.Cafardi@philips.com
Twitter:@aliciacafardi
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and enabling better outcomes across the health
continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' health
technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-showcases-data-driven-cardiology-solutions-at-2017-american-college-of-cardiology-conference-acc17-300425275.html
SOURCE Royal Philips